SKB264 +/- KL-A167 in Recurrent or Metastatic Triple-negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability and preliminary antitumor
activity of SKB264 with/without KL-A167 in patients with unresectable locally advanced,
recurrent or metastatic TNBC.The study is divided into two parts.Part 1: exploratory phase of
the efficacy and safety of the combination treatment. Part 2: randomized controlled phase,The
subjects will be randomized in a 1:1 ratio to treatment group for SKB264 + KL-A167 or SKB264
.
Phase:
Phase 2
Details
Lead Sponsor:
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.